



3412/1A/US (PHA 4140.6)
PATENT

164
TECHNICAL 1600/2900

APR 22 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of M. Obukowicz et al.
Serial No. 10/022,320
Filed December 13, 2001
Confirmation No. 1614
For SELECTIVE COX-2 INHIBITION FROM NON-EDIBLE PLANT EXTRACTS

April 17, 2002

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

A check in the amount of \$180.00 is enclosed to cover the fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement.

04/19/2002 SSANDARA 00000028 10022320

01 FC:126

180.00 OP

Respectfully submitted,

Kathryn J. Doty, Reg. No. 40,593
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

KJDMkd

Express Mail Label No. EL937979435US



04-78-02

#1651

3475/1A/US (PHA 4140.7)
PATENT

TECH CENTER 1600/2900

RECEIVED
APR 22 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of M. Obukowicz et al.
Serial No. 10/022,320
Filed December 13, 2001
Confirmation No. 4101
For SELECTIVE COX-2 INHIBITION FROM NON-EDIBLE PLANT EXTRACTS

April 17, 2002

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

A check in the amount of \$180.00 is enclosed to cover the fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement.

Respectfully submitted,

Kathryn J. Doty, Reg. No. 40,593
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

04/19/2002 65000000 10000000
01 FC:126 180.00 OP

KJDMkd

Express Mail Label No. EL937979449US

04/18/02

1614\$

PTO/SB/08A

APR 17 2002

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

APR 16 2002

Sheet 1 of 9

Complete if Known

Application Number	10/022,320
Filing Date	12-13-2001
Confirmation Number	4956
First Named Inventor	M. Obukowicz
Group Art Unit	1614
Attorney Docket No.	3412/1A/US (PHA 4140.6)

TECH CENTER 1600/2900

APR 22 2002

RECEIVED

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	4,613,591	B1	Aburada et al.	09-23-1986
	2	5,380,738	B1	Norman et al.	01-10-1995
	3	5,344,991	B1	Reitz et al.	09-06-1994
	4	5,393,790	B1	Reitz et al.	02-28-1995
	5	5,466,823	B1	Talley et al.	11-14-1995
	6	5,521,207	B1	Graneto	05-28-1996
	7	5,633,272	B1	Talley et al.	05-27-1997
	8	5,753,688	B1	Talley et al.	05-19-1998
	9	5,760,068	B1	Talley et al.	06-02-1998
	10	5,811,425	B1	Woods et al.	09-22-1998
	11	5,932,598	B1	Talley et al.	08-03-1999

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

PTO/SB/08A

APR 17 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/022,320
Filing Date	12-13-2001
Confirmation Number	4956
First Named Inventor	M. Obukowicz
Group Art Unit	1614
Attorney Docket No.	3412/1A/US (PHA 4140.6)

Sheet 2 of 9

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	12	WO	94/15932	A1	G.D. Searle & Co.	07-21-1994	
	13	WO	95/15316	A1	G.D. Searle & Co.	06-08-1995	
	14	WO	00/74696	A1	Oxford Natural Products PLC	12-14-2000	
	15	JP	4208222		Tsumura & co.	07-29-1992	X
	16	JP	4005237	A	Nonogawa Shoji:kk (abstract)	01-09-1992	
	17	JP	2000236835		Seika et al. (abstract)	09-05-2000	
	18	EP	248215	B1	Popp et al.	12-09-1987	
	19	WO	94/12165	A	Wellcome et al.	06-09-1994	
	20	WO	94/14780	A	Wellcome et al.	07-07-1994	
	21	WO	93/13055	A	Glaxo Wellcome Inc.	07-08-1993	
	22	WO	95/11231	A	Bergmanis et al.	04-27-1995	

 Examiner
Signature

 Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

APR 17 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

Complete if Known

Application Number	10/022,320
Filing Date	12-13-2001
Confirmation Number	4956
First Named Inventor	M. Obukowicz
Group Art Unit	1614
Attorney Docket No.	3412/1A/US (PHA 4140.6)

3

of

9

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	23	KASE, et al., Mechanisms by which Hange-shashin-to reduces prostaglandin E2 levels, <i>Biol. Pharm. Bull.</i> , 1998, pp. 1277-1281, Vol. 21, No. 12.	
	24	RINGBOM et al., Ursolic Acid from <i>Plantago major</i> , a Selective Inhibitor of Cyclooxygenase-2 Catalyzed Prostaglandin Biosynthesis, <i>J. Nat. Prod.</i> , 1998, pp. 1212-1215, Vol. 61, No. 10.	
	25	PENNISI, E., Building a Better Aspirin, <i>Science</i> , 1998, pp. 1191-1192, Vol. 280.	
	26	RESCH et al., 5-Lipoxygenase and Cyclooxygenase-1 Inhibitory Active Compounds from <i>Atractylodes Lancea</i> , <i>J. Nat. Prod.</i> , 1998, pp. 347-350, Vol. 61.	
	27	RUBIN, et al., Pharmacokinetics, Safety, and Ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase, <i>Agents Actions Suppl.</i> , 1991, pp. 103-116, Vol. 35. (abstract only)	
	28	CARTER, et al., 5-Lipoxygenase inhibitory activity of Zileuton, <i>J. Pharmacol. & Exp. Ther.</i> , 1991, pp. 929-937, Vol. 256, Vol. 3.	
	29	SUBBARAMAIAH et al., Resveratrol Inhibits the Expression of Cyclooxygenase-2 in Human Mammary and Oral Epithelial Cells, <i>Pharmaceutical Biology</i> , 1998, pp. 35-43, Vol. 36.	
	30	BINGOL et al., A Review of Terrestrial Plants and Marine Organisms Having Antiinflammatory Activity. <i>International Journal of Pharmacognosy</i> , 1995, pp. 81-97, Vol. 33, No. 2.	
	31	MARNETT et al., Arachidonic Acid Oxygenation by COX-1 and COX-2, <i>The Journal of Biological Chemistry</i> , 1999, pp. 22903-22906, Vol. 274, No. 33.	
	32	KALGUTKAR et al., Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2, <i>Science</i> , 1998, pp. 1268-1270, Vol. 280.	
	33	KALGUTKAR, et al., Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective Cox-2 Inhibitors, <i>PNAS</i> , 2000, pp. 925-930, Vol. 97, No. 2.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/022,320
Filing Date	12-13-2001
Confirmation Number	4956
First Named Inventor	M. Obukowicz
Group Art Unit	1614
Attorney Docket No.	3412/1A/US (PHA 4140.6)

TELEPHONE 1800/2900

APR 22 2002

RECEIVED

34	BATRISTINI et al., COX-1 and COX-2: Toward the development of More selective NSAIDs, <i>DN&P</i> , 1994, pp. 50-512, Vol. 7, No. 8.	
35	MITCHELL et al., Cyclooxygenase-2: Regulation and Relevance in Inflammation, <i>Biochemical Pharmacology</i> , 1995, pp. 1535-1542, Vol. 50, No. 10.	
36	WHITEHOUSE et al., Over the counter (OTC) oral remedies for arthritis and rheumatism: how effective are they?, <i>Inflammopharmacology</i> , 1999, pp. 89-105, Vol. 7, No. 2.	
37	DEWITT et al., The Differential Susceptibility of Prostaglandin Endoperoxide H Synthases-1 and -2 to Nonsteroidal Anti-Inflammatory Drugs: Aspirin Derivatives as Selective Inhibitors, <i>Med Chem Res</i> , 1995, pp. 325-343, Vol. 5.	
38	DUKE, J., Clippings from my COX Box, <i>Journal of Medicinal Food</i> , 1998/1999, pp. 293-298, Vol. 1, No. 4.	
39	MCADAM et al., Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of Cox-2, <i>Proc. Nat. Acad. Sci. USA</i> , 1999, pp. 272-277, Vol. 96.	
40	O'NEILL et al., Overexpression of Human Prostaglandin G/H Synthase-1 and -2 by Recombinant Vaccinia Virus: Inhibition by Nonsteroidal Anti-Inflammatory Drugs and Biosynthesis of 15-Hydroxyeicosatetraenoic Acid, <i>Mole. Pharmacol</i> , 1994, pp. 245-254, Vol. 45.	
41	AUERBACH et al., A Spectrophotometric Microtiter-Based Assay for the Detection of Hydroperoxy Derivatives of Linoleic Acid, <i>Anal. Biochem</i> , 1992, pp. 375-380, Vol. 201.	
42	NOWLIN et al., A Novel Cyclic Pentapeptide Inhibits $\alpha 4\beta 1$ and $\alpha 5\beta 1$ Integrin-mediated cell Adhesion, <i>J. Biol. Chem</i> , 1993, pp. 20352-20359, Vol. 268.	
43	STOLTENBORG et al., A fluorescent cellular adhesion assay using insect cell produced human VCAM1, <i>J. Immunological Methods</i> , 1994, pp. 59-68, Vol. 175.	
44	WELKER et al., Glucocorticoid-Induced Modulation of Cytokine Secretion from Normal and Leukemic Human Myelomonocytic Cells, <i>International Arch of Allergy and Immunology</i> , 1996, pp. 110-115, Vol. 109.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		<p style="text-align: center;">Complete if Known</p> <p>Application Number 10/022,320</p> <p>Filing Date 12-13-2001</p> <p>Confirmation Number 4956</p> <p>First Named Inventor M. Obukowicz</p> <p>Group Art Unit 1614</p>	
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT OF APPLICANT</p> <p style="text-align: center;">(use as many sheets as necessary)</p>			
<p style="text-align: center;">Sheets of 9</p>			
<p style="text-align: center;">Attorney Docket No. 3412/1A/US (PHA 4140.6)</p>			
<p style="text-align: center;">PATENT & TRADEMARK OFFICE</p>			

45	KOIZUMI et al., Inhibitors of IL-2 Production and IL-2 Receptor Expression in Human Leukemic T-Cell Line, Jurkat, <i>Cellular Immunology</i> , 1986, pp. 469-475, Vol. 103.
46	COHEN et al., Cytokine Function, <i>Am. J. Clin. Pathol.</i> , 1996, pp. 589-598, Vol. 105., No. 5.
47	HENDERSON et al., Therapeutic potential of cytokine manipulation, <i>TIPS</i> , 1992, pp. 145-152, Vol. 13.
48	ELIAS et al., Synergistic Stimulation of Fibroblast Prostaglandin Production by Recombinant Interleukin 1 and Tumor Necrosis Factor, <i>J. Immunol.</i> , 1987, pp. 3812-3816, Vol. 138.
49	LENARDO et al., NF- κ B: A Pleiotrophic Mediator of Inducible and Tissue-Specific Gene Control, <i>Cell</i> , 1989, pp. 227-229, Vol. 58.
50	MALOFF et al., Development of an RIA-based primary screen for IL-1 antagonists, <i>Clin. Chim. Acta.</i> , 1988, pp. 73-78, Vol. 180.
51	KARTTUMEN et al., Measurement of ligand-induced activation in single viable T cells using the <i>lacZ</i> reporter gene, <i>Proc. Nat'l. Acad. Sci.</i> , 1991, pp. 3972-3976, Vol. 88.
52	EMMEL et al., Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation, <i>Science</i> , 1989, pp. 1617-1620, Vol. 246.
53	CHANG et al., The Influence of Chinese Traditional Medicine on the Production and Activity of Interleukin 1, <i>Chinese J. Microbiol. Immunol.</i> , 1993, pp. 15-24, Vol. 26.
54	MIN, K.R. et al. (-)-Epiafzelechin: Cyclooxygenase-1 Inhibitor and Anti-Inflammatory Agency from Aerial Parts of <i>Celastrus orbiculatus</i> , <i>Planta Med.</i> , 1999, pp. 460-462, Vol. 65.
55	LEE et al. a-Viniferin: A Prostaglandin H2 Synthase Inhibitor from Root of <i>Carex humilis</i> , <i>Planta Med.</i> , 1998, pp. 195-290, Vol. 64.
56	NOREEN et al., Flavan-3-ols isolated from Some Medicinal Plants Inhibiting COX-1 and COX-2 Catalysed Prostaglandin Biosynthesis, 1998, pp. 520-524, Vol. 64.
58	DANZ et al., Identification and Isolation of the Cyclooxygenase-2 Inhibitory Principle in <i>Isatis tinctoria</i> , <i>Planta Med.</i> , 67, pp. 411-416, Vol. 67.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Use as many sheets as necessary)

Complete if Known

Application Number	10/022,320
Filing Date	12-13-2001
Confirmation Number	4956
First Named Inventor	M. Obukowicz
Group Art Unit	1614
Attorney Docket No.	3412/1A/US (PHA 4140.6)

6

of

9

59	TAYLOR et al., COX-1 inhibitory activity in extracts from <i>Eucomis</i> L'Herit. species, <i>J. Ethnopharmacol.</i> , 2001, pp. 257-265, Vol. 76, Nos. 2-3.
60	CHOU et al., The inhibitory effect of common traditional anti-rheumatic herb formulas on prostaglandin E and interleukin 2 in vitro: A comparative study with <i>Tripterygium wilfordii</i> , <i>J. Ethnopharmacol.</i> , 1998, pp. 167-171, Vol. 62, No. 2.
61	ZSCHOCKE et al., 5-Lipoxygenase and Cyclooxygenase Inhibitory Active Constituents from Qianghuo (<i>Notopterygium incisum</i>), <i>Planta Med.</i> , 1997, pp. 203-206, Vol. 63.
62	KIM et al., Effects of naturally- occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea pigs, <i>Prostaglandins Leukot. Essent. Fatty Acids</i> , 1998 58(1); pp. 17-24.
63	TUNON et al., Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis, <i>J. Ethnopharmacol.</i> , 48, 1995, pp. 61-76.
64	YOU et al., Inhibition of Cyclooxygenase/Lipoxygenase from Human Platelets by Polyhydroxylated/Methoxylated Flavonoids Isolated from Medicinal Plants, <i>Arch. Pharm. Res.</i> , 1999, pp. 18-24, Vol. 22, No. 1.
65	SEGURA et al., Anti-Inflammatory Activity of Dichloromethane Extract of <i>Heterotheca inuloids in Vivo</i> and <i>in Vitro</i> , <i>Planta Med.</i> , 2000, pp. 553-555, Vol. 66.
66	DUNSTAN et al., Evaluation of some Samoan and Peruvian medicinal plants by prostaglandin biosynthesis and rat ear oedema assays, <i>J. Ethnopharmacol.</i> , 1997, pp. 35-56, Vol. 57, No. 1.
67	ABAD et al., The Activity of Flavonoids Extracted from <i>Tanacetum microphyllum</i> DC. (Compositae) on Soybean Lipoxygenase and Prostaglandin Synthetase, <i>Gen. Pharmacol.</i> , 1995, pp. 815-819, Vol. 26, No. 4.
68	ABAD et al., Anti-inflammatory Activity of Hydroxyachillin, a Sesquiterpene Lactone from <i>Tanacetum microphyllum</i> , <i>Planta Med.</i> , 1994, pp. 228-231, Vol. 60.
69	WANG et al., Antioxidant and Antiinflammatory Activities of Anthocyanins and Their Aglycon, Cyanidin, from Tart Cherries, <i>J. Nat. Prod.</i> , 1999, pp. 294- 296, Vol. 62, No. 2.

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See indicated Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

APR 17 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

APR 16 2002

Complete if Known

Application Number	10/022,320
Filing Date	12-13-2001
Confirmation Number	4956
First Named Inventor	M. Obukowicz
Group Art Unit	1614
Attorney Docket No.	3412/1A/US (PHA 4140.6)

7

of

9

70

RESCH et al., Further Phenols and Polyacetylenes from the Rhizomes of *Atractylodes lancea* and their Anti-Inflammatory Activity, *Planta Med.*, 2001, pp. 437-442. Vol. 67.

71

JAGER et al., Screening of Zulu medicinal plants for prostaglandin synthesis inhibitors, *J. Ethnopharmacol.*, 1996, pp. 95-100, Vol. 52, No. 2.

72

RINGBOM et al., COX-2 Inhibitory Effects of Naturally Occurring and Modified Fatty Acids, *J. Nat. Prod.*, 2001, pp. 745-749, Vol. 64, No. 6.

73

NOREEN et al., Development of a Radiochemical Cyclooxygenase-1 and -2 in Vitro Assay for Identification of Natural Products as Inhibitors of Prostaglandin Biosynthesis, *J. Nat. Prod.*, 1998, Vol. 61, No. 1.

74

MOON et al., A new class of COX-2 inhibitor, rutaecarpine from *Evodia rutaecarpa*, *Inflamm. Res.*, 1999, Vol. 48, pp. 621-625.

75

REDDY et al., Selective Inhibition of Cyclooxygenase-2 by C-Phycocyanin, a Biliprotein from *Spirulina platensis*, *Biochem. Biophys. Res. Commun.*, 2000, Vol. 277, No. 3.

76

LIU et al., Inhibitory Effects of *Angelica pubescens f. biserrata* on 5-Lipoxygenase and Cyclooxygenase, *Planta Med.*, 1998, pp. 525-529, Vol. 64.

77

NEWMARK et al. (2000) Beyond Aspirin: Nature's Answer to Arthritis, Cancer, and Alzheimer's Disease. Hohm Press, Prescott, AZ. (Table of Contents only).

78

LAVALLE, James B. (2001) The COX-2 Connection: Natural Breakthrough Treatments for Arthritis, Alzheimer's, and Cancer. Healing Arts Press. (Table of Contents only).

79

TYLER, Varro E., Phytomedicines: Back to the Future, *J. Nat. Prod.*, 1999, pp. 1589-1592.

80

MICHALUART et al., Inhibitory Effects of Caffeic Acid Phenethyl Ester on the Activity and Expression of Cyclooxygenase-2 in Human Oral Epithelial Cells and in a Rat Model of Inflammation, *Cancer Res.*, 1999, Vol. 59, pp. 2347-2352.

81

SUBBARAMAIAH et al., Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells, *Cancer Res.*, 2000, Vol. 60, pp. 2399-2404.

82

SUBBARAMAIAH et al., Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells, *Ann. N.Y. Acad. Sci.*, 1999, Vol. 889, pp. 214-223.

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

APR 17 2002

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number 10/022,320

Filing Date 12-13-2001

Confirmation Number 4956

First Named Inventor M. Obukowicz

Group Art Unit 1614

Sheet 9

Attorney Docket No. 3412/1A/US (PHA 4140.6)

83	SUBBARAMAIIH et al., Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells, <i>J. Biol. Chem.</i> , 1998, 273(34):21875-21882.
84	WILLIAMS et al. The flavonoids of <i>Tanacetum parthenium</i> and <i>T. vulgare</i> and their anti-inflammatory properties, <i>Phytochemistry</i> , 1999, pp. 417-423, Vol. 51, No. 3.
85	REDDY et al., Studies on Anti-Inflammatory Activity of Spice Principles and Dietary n-3 Polyunsaturated Fatty Acids on Carrageenan-Induced Inflammation in Rats, <i>Ann. Nutr. Metab.</i> , 1994, pp. 349-358.
86	JUERGENS, U.R., et. al., The Anti-Inflammatory Activity of L-Menthol Compared to Mint Oil in Human Monocytes In Vitro: A Novel Perspective For Its Therapeutic Use in Inflammatory Diseases, <i>Eur. J. Med. Res.</i> , 1998, pp. 539-545.
87	JUERGENS, U.R., et. al., Inhibition of Cytokine Production And Arachidonic Acid Metabolism By Eucalyptol (1.8-Cineole) In Human Blood Monocytes In Vitro, <i>Eur. J. Med. Res.</i> , 1998, pp. 508-510.
88	HAQQI et al., Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea, <i>Proc. Natl. Acad. Sci. USA</i> , 1999, pp. 4524-4529, Vol. 96.
89	ALANKO et al., Modulation of arachidonic acid metabolism by phenols: Relation to their structure and anti-oxidant/pro-oxidant properties, <i>Free Radical Biology and Medicine</i> , 1999, pp. 193-201, Vol. 26.
90	ZHANG et. al., Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells, <i>Carcinogenesis</i> , 1999, Vol. 20, No. 3.
91	LINDSEY et al., Screening of plants used by Southern African traditional healers in the treatment of dysmenorrhoea for prostaglandin-synthesis inhibitors and uterine relaxing activity, <i>Journal of Ethnopharmacology</i> , 1999, pp. 9-14, Vol. 64.
92	JANG et al., Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, <i>Science</i> , 1997, pp. 218-220, Vol. 275.
93	GIERSE et al., A single Amino Acid Difference Between Cyclooxygenase-1 (COX-1) and -2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors, <i>The Journal of Biological Chemistry</i> , 1996, pp. 15810-15814, Vol. 271, No. 26.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

APR 17 2002

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

APR 16 2002

MAIL DATE CANCELLED

Application Number	10/022,320
Filing Date	12-13-2001
Confirmation Number	4956
First Named Inventor	M. Obukowicz
Group Art Unit	1614
Attorney Docket No.	3412/1A/US (PHA 4140.6)

	94	Nexrutine brochure for Remedief, Triple Action Pain Management with Natural Cox-2 Inhibitor. Undated	
	95	Hawley's Condensed Chemical Dictionary, 13th Edition, Revised by Lewis, 1997, page 736.	
	96	J. Heterocyclic Chem. 1982, pp. 193-200, Vol. 19, No. 1.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.